Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 20 |
| List of Tables | 18 | 3 |
| List of Figures | 21 | 1 |
| Introduction | 22 | 1 |
| Global Markets Direct Report Coverage | 22 | 1 |
| Crohn's Disease (Regional Enteritis) Overview | 23 | 1 |
| Therapeutics Development | 24 | 2 |
| Pipeline Products for Crohn's Disease (Regional Enteritis) Overview | 24 | 1 |
| Pipeline Products for Crohn's Disease (Regional Enteritis) Comparative Analysis | 25 | 1 |
| Crohn's Disease (Regional Enteritis) Therapeutics under Development by Companies | 26 | 8 |
| Crohn's Disease (Regional Enteritis) Therapeutics under Investigation by Universities/Institutes | 34 | 1 |
| Crohn's Disease (Regional Enteritis) Pipeline Products Glance | 35 | 4 |
| Late Stage Products | 35 | 1 |
| Clinical Stage Products | 36 | 1 |
| Early Stage Products | 37 | 1 |
| Unknown Stage Products | 38 | 1 |
| Crohn's Disease (Regional Enteritis) Products under Development by Companies | 39 | 9 |
| Crohn's Disease (Regional Enteritis) Products under Investigation by Universities/Institutes | 48 | 1 |
| Crohn's Disease (Regional Enteritis) Companies Involved in Therapeutics Development | 49 | 79 |
| 4D Pharma Plc | 49 | 1 |
| 4SC AG | 50 | 1 |
| AB Science SA | 51 | 1 |
| AbbVie Inc | 52 | 1 |
| Alfa Wassermann S.p.A | 53 | 1 |
| Alteogen Inc. | 54 | 1 |
| Amgen Inc. | 55 | 1 |
| Ampio Pharmaceuticals, Inc. | 56 | 1 |
| ARA Healthcare Pvt. Ltd. | 57 | 1 |
| Arena Pharmaceuticals, Inc. | 58 | 1 |
| Astellas Pharma Inc. | 59 | 1 |
| BioLingus AG | 60 | 1 |
| Bionovis SA | 61 | 1 |
| BioTherapeutics Inc. | 62 | 1 |
| Calypso Biotech SA | 63 | 1 |
| Celgene Corporation | 64 | 1 |
| ChemoCentryx, Inc. | 65 | 1 |
| ChironWells GmbH | 66 | 1 |
| CLL Pharma | 67 | 1 |
| Coherus BioSciences, Inc. | 68 | 1 |
| Commence Bio, Inc. | 69 | 1 |
| Daiichi Sankyo Company, Limited | 70 | 1 |
| DBV Technologies S.A. | 71 | 1 |
| Eisai Co., Ltd. | 72 | 1 |
| Eli Lilly and Company | 73 | 1 |
| Enterome Bioscience SA | 74 | 1 |
| Enzo Biochem, Inc. | 75 | 1 |
| Epirus Biopharmaceuticals, Inc. | 76 | 1 |
| Ferring International Center S.A. | 77 | 1 |
| Galapagos NV | 78 | 1 |
| Genentech, Inc. | 79 | 1 |
| Genor BioPharma Co., Ltd. | 80 | 1 |
| Gilead Sciences, Inc. | 81 | 1 |
| iCo Therapeutics Inc. | 82 | 1 |
| Idera Pharmaceuticals, Inc. | 83 | 1 |
| Immune Response BioPharma, Inc. | 84 | 1 |
| Innovent Biologics, Inc. | 85 | 1 |
| Johnson &Johnson | 86 | 1 |
| Jyant Technologies, Inc. | 87 | 1 |
| Kang Stem Biotech Co., Ltd. | 88 | 1 |
| KPI Therapeutics, Inc. | 89 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 90 | 1 |
| MedImmune, LLC | 91 | 1 |
| Merck &Co., Inc. | 92 | 1 |
| Mesoblast Limited | 93 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 94 | 1 |
| Momenta Pharmaceuticals, Inc. | 95 | 1 |
| Mycenax Biotech Inc. | 96 | 1 |
| Neovacs SA | 97 | 1 |
| Oncobiologics, Inc. | 98 | 1 |
| Oncodesign SA | 99 | 1 |
| OSE Immunotherapeutics | 100 | 1 |
| Pfenex Inc. | 101 | 1 |
| Pfizer Inc. | 102 | 1 |
| Pieris Pharmaceuticals, Inc. | 103 | 1 |
| Pluristem Therapeutics Inc. | 104 | 1 |
| Protalix BioTherapeutics, Inc. | 105 | 1 |
| Qu Biologics Inc. | 106 | 1 |
| Re-Pharm Limited | 107 | 1 |
| RedHill Biopharma Ltd. | 108 | 1 |
| Sandoz International GmbH | 109 | 1 |
| SATT North SAS | 110 | 1 |
| Second Genome, Inc. | 111 | 1 |
| Selexys Pharmaceuticals Corporation | 112 | 1 |
| Selvita S.A. | 113 | 1 |
| Shire Plc | 114 | 1 |
| Sigmoid Pharma Limited | 115 | 1 |
| Soligenix, Inc. | 116 | 1 |
| Stelic Institute &Co., Inc. | 117 | 1 |
| Sylentis S.A.U. | 118 | 1 |
| TaiwanJ Pharmaceuticals Co., Ltd. | 119 | 1 |
| Takeda Pharmaceutical Company Limited | 120 | 1 |
| Therapeutic Proteins International, LLC | 121 | 1 |
| Tiziana Life Sciences Plc | 122 | 1 |
| Trino Therapeutics Limited | 123 | 1 |
| TxCell SA | 124 | 1 |
| Ventria Bioscience | 125 | 1 |
| Virobay Inc. | 126 | 1 |
| Xbrane Biopharma AB | 127 | 1 |
| Crohn's Disease (Regional Enteritis) Therapeutics Assessment | 128 | 23 |
| Assessment by Monotherapy Products | 128 | 1 |
| Assessment by Combination Products | 129 | 1 |
| Assessment by Target | 130 | 8 |
| Assessment by Mechanism of Action | 138 | 9 |
| Assessment by Route of Administration | 147 | 2 |
| Assessment by Molecule Type | 149 | 2 |
| Drug Profiles | 151 | 264 |
| (clarithromycin + clofazimine + rifabutin) Drug Profile | 151 | 7 |
| ABS-11 Drug Profile | 158 | 1 |
| adalimumab Drug Profile | 159 | 8 |
| adalimumab biosimilar Drug Profile | 167 | 2 |
| adalimumab biosimilar Drug Profile | 169 | 2 |
| adalimumab biosimilar Drug Profile | 171 | 1 |
| adalimumab biosimilar Drug Profile | 172 | 1 |
| adalimumab biosimilar Drug Profile | 173 | 1 |
| adalimumab biosimilar Drug Profile | 174 | 1 |
| adalimumab biosimilar Drug Profile | 175 | 3 |
| adalimumab biosimilar Drug Profile | 178 | 1 |
| adalimumab biosimilar Drug Profile | 179 | 1 |
| adalimumab biosimilar Drug Profile | 180 | 2 |
| adalimumab biosimilar Drug Profile | 182 | 2 |
| adalimumab biosimilar Drug Profile | 184 | 1 |
| adalimumab biosimilar Drug Profile | 185 | 1 |
| adalimumab biosimilar Drug Profile | 186 | 1 |
| adalimumab biosimilar Drug Profile | 187 | 1 |
| Alequel Drug Profile | 188 | 1 |
| ALLO-ASC Drug Profile | 189 | 1 |
| amiselimod hydrochloride Drug Profile | 190 | 2 |
| Ampion Drug Profile | 192 | 8 |
| Antisense RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders Drug Profile | 200 | 1 |
| ARABS-8 Drug Profile | 201 | 1 |
| ATAF-11 Drug Profile | 202 | 1 |
| bertilimumab Drug Profile | 203 | 4 |
| Biologic for Ulcerative Colitis and Crohn's Disease Drug Profile | 207 | 1 |
| brazikumab Drug Profile | 208 | 2 |
| BT-11 Drug Profile | 210 | 2 |
| CALY-001 Drug Profile | 212 | 1 |
| CCX-507 Drug Profile | 213 | 1 |
| Cellular Immunotherapy for Crohn s Disease Drug Profile | 214 | 1 |
| certolizumab pegol biosimilar Drug Profile | 215 | 1 |
| certolizumab pegol biosimilar Drug Profile | 216 | 1 |
| CMB-200 Drug Profile | 217 | 1 |
| cyclosporine Drug Profile | 218 | 1 |
| Drug for Crohn's Disease Drug Profile | 219 | 1 |
| Drug to Inhibit Calpain-2 for Crohn's Diseases and Ulcerative Colitis Drug Profile | 220 | 1 |
| E-6011 Drug Profile | 221 | 2 |
| EB-110 Drug Profile | 223 | 1 |
| EB-8018 Drug Profile | 224 | 1 |
| EGS-21 Drug Profile | 225 | 1 |
| etanercept biosimilar Drug Profile | 226 | 2 |
| etrasimod Drug Profile | 228 | 2 |
| etrolizumab Drug Profile | 230 | 2 |
| ETX-201 Drug Profile | 232 | 1 |
| FE-999301 Drug Profile | 233 | 1 |
| FFP-102 Drug Profile | 234 | 1 |
| FFP-104 Drug Profile | 235 | 1 |
| filgotinib Drug Profile | 236 | 9 |
| foralumab Drug Profile | 245 | 1 |
| Furestem-CD Drug Profile | 246 | 1 |
| GLPG-1205 Drug Profile | 247 | 2 |
| GS-5745 Drug Profile | 249 | 2 |
| IK-003 Drug Profile | 251 | 1 |
| IK-004 Drug Profile | 252 | 1 |
| IMO-9200 Drug Profile | 253 | 2 |
| infliximab Drug Profile | 255 | 4 |
| infliximab biosimilar Drug Profile | 259 | 1 |
| infliximab biosimilar Drug Profile | 260 | 1 |
| infliximab biosimilar Drug Profile | 261 | 3 |
| infliximab biosimilar Drug Profile | 264 | 1 |
| infliximab biosimilar Drug Profile | 265 | 1 |
| infliximab biosimilar Drug Profile | 266 | 3 |
| infliximab biosimilar Drug Profile | 269 | 1 |
| infliximab biosimilar Drug Profile | 270 | 1 |
| INV-88 Drug Profile | 271 | 1 |
| IR-777 Drug Profile | 272 | 1 |
| JNJ-40346527 Drug Profile | 273 | 1 |
| JT-07 Drug Profile | 274 | 1 |
| KRP-203 Drug Profile | 275 | 2 |
| LY-3074828 Drug Profile | 277 | 1 |
| masitinib Drug Profile | 278 | 14 |
| molgramostim Drug Profile | 292 | 1 |
| mongersen sodium Drug Profile | 293 | 2 |
| Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease Drug Profile | 295 | 1 |
| Monoclonal Antibodies to Inhibit MMP-2 and MMP-9 for Immunology and Gastrointestinal Disorders Drug Profile | 296 | 1 |
| Monoclonal Antibody to Inhibit IL-23 for Crohn's Disease and Psoriasis Drug Profile | 297 | 1 |
| Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Respiratory Infections Drug Profile | 298 | 1 |
| MP-196 Drug Profile | 299 | 1 |
| naltrexone hydrochloride Drug Profile | 300 | 2 |
| naltrexone hydrochloride Drug Profile | 302 | 3 |
| naltrexone hydrochloride Drug Profile | 305 | 1 |
| NRG-4 Drug Profile | 306 | 1 |
| Ova-Treg Drug Profile | 307 | 4 |
| ozanimod hydrochloride Drug Profile | 311 | 6 |
| PAC-GI Drug Profile | 317 | 1 |
| Peptides to Activate CEACAM5 for Crohn's Disease Drug Profile | 318 | 1 |
| PF-04236921 Drug Profile | 319 | 2 |
| PF-06480605 Drug Profile | 321 | 1 |
| PF-06651600 Drug Profile | 322 | 1 |
| PH-44 Drug Profile | 323 | 1 |
| PH-46A Drug Profile | 324 | 1 |
| PH-5 Drug Profile | 325 | 1 |
| PRS-190 Drug Profile | 326 | 1 |
| PTG-200 Drug Profile | 327 | 1 |
| QBECO-SSI Drug Profile | 328 | 4 |
| Recombinant Protein for Crohn's Disease Drug Profile | 332 | 1 |
| Recombinant Protein for Crohn s Disease and Ulcerative Colitis Drug Profile | 333 | 1 |
| Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis Drug Profile | 334 | 1 |
| remestemcel-L Drug Profile | 335 | 6 |
| rifaximin Drug Profile | 341 | 4 |
| rifaximin DR Drug Profile | 345 | 1 |
| risankizumab Drug Profile | 346 | 3 |
| RP-0217 Drug Profile | 349 | 1 |
| SEL-212 Drug Profile | 350 | 1 |
| SelK-2 Drug Profile | 351 | 1 |
| SGM-1019 Drug Profile | 352 | 1 |
| SGX-203 Drug Profile | 353 | 2 |
| SHP-647 Drug Profile | 355 | 2 |
| Small Molecule for Crohn s Disease Drug Profile | 357 | 1 |
| Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease Drug Profile | 358 | 1 |
| Small Molecule to Agonize Mu Opioid Receptor for Crohn's Disease and Ulcerative Colitis Drug Profile | 359 | 1 |
| Small Molecules for Crohn s Disease and Ulcerative Colitis Drug Profile | 360 | 1 |
| Small Molecules to Antagonize CCR9 for Crohn's Disease and Ulcerative Colitis Drug Profile | 361 | 1 |
| Small Molecules to Antagonize Integrin Alpha 4 and Integrin Beta 7 for Inflammatory Diseases Drug Profile | 362 | 1 |
| Small Molecules to Inhibit FimH for Urinary Tract Infections and Crohn s Disease Drug Profile | 363 | 1 |
| Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis Drug Profile | 364 | 1 |
| SQ-641 Drug Profile | 365 | 1 |
| Stem Cell Therapy for Autoimmune Diseases Drug Profile | 366 | 2 |
| Stem Cell Therapy for Inflammatory Bowel Disease Drug Profile | 368 | 2 |
| STNM-01 Drug Profile | 370 | 1 |
| SYN-1002 Drug Profile | 371 | 1 |
| Synthetic Peptides To Inhibit Interleukin-6 for Crohn's Disease and Rheumatoid Arthritis Drug Profile | 372 | 1 |
| TAK-828 Drug Profile | 373 | 1 |
| teduglutide Drug Profile | 374 | 6 |
| Thetanix Drug Profile | 380 | 1 |
| U-2902 Drug Profile | 381 | 2 |
| upadacitinib tartrate Drug Profile | 383 | 2 |
| ustekinumab Drug Profile | 385 | 6 |
| Vaccine to Target TNF Alpha for Crohn's Disease, Rheumatoid Arthritis and Psoriasis Drug Profile | 391 | 4 |
| VBY-036 Drug Profile | 395 | 2 |
| VBY-129 Drug Profile | 397 | 1 |
| vedolizumab Drug Profile | 398 | 5 |
| VEN-100 Drug Profile | 403 | 2 |
| VEN-120 Drug Profile | 405 | 1 |
| vercirnon sodium Drug Profile | 406 | 3 |
| vidofludimus Drug Profile | 409 | 4 |
| zucapsaicin Drug Profile | 413 | 2 |
| Crohn's Disease (Regional Enteritis) Dormant Projects | 415 | 12 |
| Crohn's Disease (Regional Enteritis) Discontinued Products | 427 | 2 |
| Crohn's Disease (Regional Enteritis) Product Development Milestones | 429 | 12 |
| Featured News &Press Releases | 429 | 1 |
| Jul 17, 2016: SB5, An Adalimumab Biosimilar Referencing Humira, Accepted for Review by European Medicines Agency | 429 | 1 |